Related Experiment Videos
Mitoxantrone: benefits and risks in multiple sclerosis patients.
V Martinelli1, M Radaelli, L Straffi
1Neurology Department, INSPE, University IRCCS San Raffaele, Milan, Italy. v.martinelli@hsr.it
Summary
Mitoxantrone (MTX) effectively reduces disability and relapses in multiple sclerosis (MS) patients. However, serious risks like cardiotoxicity and leukemia necessitate careful benefit-risk assessment for MS treatment.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- Mitoxantrone (MTX) is a synthetic antineoplastic cytotoxic drug.
- Its efficacy in multiple sclerosis (MS) is supported by observational studies and four randomized controlled trials (RCTs).
Purpose of the Study:
- To evaluate the efficacy of Mitoxantrone (MTX) in reducing neurological disability and clinical relapses in progressive MS patients.
- To outline the adverse events associated with MTX treatment.
Main Methods:
- Review of evidence from open-label, observational studies, and four randomized controlled clinical trials (RCTs).
Main Results:
- MTX is indicated for progressive relapsing and worsening relapsing-remitting MS.
- Common adverse events include nausea, vomiting, alopecia, infections, and leukopenia.
- Serious risks include potential cardiotoxicity and leukemia, with incidence possibly higher than previously reported.
Conclusions:
- Mitoxantrone (MTX) offers benefits for specific MS patient populations.
- Careful consideration of serious adverse events, including cardiotoxicity and leukemia, is crucial when weighing MTX treatment benefits against risks for individual MS patients.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...